EGFR and non-small cell lung carcinoma: In conclusion, although our study was terminated early owing to futility, our results showed modest clinical activity of mobocertinib in Japanese patients with NSCLC harboring EGFR exon 20 insertion mutations and did not raise any additional safety concerns.